Subject(s)
Heart Aneurysm/diagnosis , Heart Ventricles/pathology , Ventricular Outflow Obstruction/diagnosis , Adult , Diagnosis, Differential , Dyspnea/etiology , Echocardiography, Transesophageal , Heart Aneurysm/complications , Heart Aneurysm/diagnostic imaging , Heart Aneurysm/pathology , Humans , Male , Ventricular Outflow Obstruction/complications , Ventricular Outflow Obstruction/diagnostic imaging , Ventricular Outflow Obstruction/pathologySubject(s)
Anabolic Agents/adverse effects , Coronary Thrombosis/diagnosis , Myocardial Infarction/diagnosis , Steroids/adverse effects , Adult , Anabolic Agents/administration & dosage , Androstanols/administration & dosage , Androstanols/adverse effects , Angina Pectoris/etiology , Coronary Angiography , Coronary Thrombosis/chemically induced , Coronary Thrombosis/complications , Coronary Thrombosis/diagnostic imaging , Diagnosis, Differential , Electrocardiography , Humans , Male , Methandrostenolone/administration & dosage , Methandrostenolone/adverse effects , Myocardial Infarction/chemically induced , Myocardial Infarction/complications , Myocardial Infarction/diagnostic imaging , Steroids/administration & dosage , Testosterone Propionate/administration & dosage , Testosterone Propionate/adverse effectsABSTRACT
OBJECTIVE: Brain natriuretic peptide (BNP) is secreted predominantly from the ventricles in response to increased wall stress, which is known to be one of the major forces driving left ventricular (LV) remodeling. In this prospective study, we evaluated value of BNP levels in acute myocardial infarction (MI) patients for the prediction of heart failure during one year of follow-up. METHODS: Seventy-four patients with a first ST-elevation MI were examined prospectively after 5 days and 1 month with echocardiography and blood samples for BNP were obtained. Clinical events were recorded during 12 months of follow-up. Multivariate linear regression analysis was used to analyze the value of different baseline characteristics as independent predictors of LV ejection fraction (LVEF) 39 pg/ml identified LVEF
Subject(s)
Heart Failure/diagnosis , Myocardial Infarction/complications , Natriuretic Peptide, Brain/blood , Ventricular Dysfunction, Left/diagnosis , Case-Control Studies , Echocardiography , Female , Follow-Up Studies , Heart Failure/blood , Heart Failure/etiology , Humans , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/diagnostic imaging , Predictive Value of Tests , Prognosis , Prospective Studies , ROC Curve , Sensitivity and Specificity , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/etiologyABSTRACT
Recent studies demonstrate that, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers may decrease left ventricular hypertrophy (LVH) in hypertensive patients. We wanted to assess the efficacy of valsartan on echocardiographic variables of LVH in 30 mild to moderate hypertensive patients. Valsartan was found effective in controlling hypertension, also echocardiographic indices of LVH such as interventricular septum and posterior wall thickness were reduced and left ventricular mass decreased significantly. Thus valsartan favorably influences cardiac structure in hypertensive patients.